KUNMING, China and DUBLIN, Ireland, June 26 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (“Alltracel”, or “the Company”), (AIM:AP.L), the Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets is pleased to confirm that Yunnan Baiyao Group, Alltracel’s woundcare marketing partner for China, has secured regulatory approval for the first in a range of stops bleeding products featuring Alltracel’s patented m.doc(TM) technology. Specifically approval has been secured for wound pad based products and nasal sponges and product sales are targeted to commence later this year.
Yunnan Baiyao - the originator of stops bleeding solutions in China and owner of the world’s number one consumer stops bleeding brand - was appointed Alltracel’s m.doc(TM) marketing partner for China as part of a broad range partnership agreement last August.
Tony Richardson, Chief Executive Officer of Alltracel, commented:
“We are particularly pleased that Yunnan Baiyao has cleared the first regulatory hurdles on m.doc(TM) for the world’s largest consumer medical market. We are now working towards an end of year launch focusing on m.doc(TM) based stops bleeding nasal sponges initially.”
For Further Information Contact: Dublin: Denise Cronin, Alltracel: +353-1-235-2162, press@alltracel.com London: Deborah Scott, Financial Dynamics: +44-(0)207-831-3113 New York: Sean Leous, Financial Dynamics: +1-212-850-5626 Notes to Editors follow:
Yunnan Baiyao Group, (www.yunnannbaiyao.com.cn), headquartered in Kunming city of Yunnan Province, China, became a listed company on Shenzhen’s Stock Exchange in 1993 (code: 000538). Current annual sales are approximately EUR200 million with a market capitalization of almost EUR500 million; employees total over 2,050.
The Yunnan Baiyao brand is a world famous Chinese remedy formulated in 1902. It consists of various unique Chinese herbs with the ability to stop bleeding, invigorate blood circulation, speed the elimination of bruises and remove pustules. Since the launch of the product over 100 years ago, Yunnan Baiyao has built a world wide reputation as ‘Chinese Treasure’ for the treatment of injuries.
The company is mainly engaged in areas of pharmaceutical manufacturing, logistics and service of medical products, research and development of new medicines, cultivation of Chinese Traditional Medicine plants and products standardisation. The company has over 200 products in three series: Yunnan Baiyao series, Radix Notogingseng series and Ethnic medicine series, within which the company owns the intellectual property of over 30 products.
Yunnan Baiyao became Alltracel’s partner for the Chinese woundcare market in August 2005.
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London’s Alternative Investment Market in July 2001.
Alltracel’s has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel’s patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent.
- In the consumer Woundcare sector m-doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.
- Alltracel’s woundcare technology is also currently poised for entry into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following two years of scientific research including in vitro, pre-clinical and clinical trials indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
Alltracel’s patented process utilises a derivative of cellulose fibre to produce a bioactive with scientifically proven properties that aid CVH; specifically lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other bio-actives) studies to determine optimum delivery systems, formats and combinations in both the functional foods and pharmaceutical markets are underway.
- Development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Alltracel Pharmaceuticals Plc.
CONTACT: Dublin: Denise Cronin, Alltracel: +353-1-235-2162,press@alltracel.com. London: Deborah Scott, Financial Dynamics:+44-(0)207-831-3113. New York: Sean Leous, Financial Dynamics:+1-212-850-5626
